| Literature DB >> 28334506 |
Floriane Gibault1, Fabrice Bailly1, Matthieu Corvaisier2, Mathilde Coevoet1, Guillemette Huet2, Patricia Melnyk1, Philippe Cotelle1.
Abstract
Porphyrin derivatives, in particular verteporfin (VP), a photosensitizer initially designed for cancer therapy, have been identified as inhibitors of the YAP-TEAD interaction and transcriptional activity. Herein we report the efficient convergent synthesis of the dipyrrin half of protoporphyrin IX dimethyl ester (PPIX-DME), in which the sensitive vinyl group was created at the final stage by a dehydroiodination reaction. Two other dipyrrin derivatives were synthesized, including dipyrrin 19 [(Z)-2-((3,5-dimethyl-4-vinyl-2H-pyrrol-2-ylidene)methyl)-3,5-dimethyl-4-vinyl-1H-pyrrole], containing two vinyl groups. We found that VP and dipyrrin 19 showed significant inhibitory effects on TEAD transcriptional activity in MDA-MB-231 human breast cancer cells, whereas other compounds did not show significant changes. In addition, we observed a marked decrease in both YAP and TAZ levels following VP treatment, whereas dipyrrin 19 treatment primarily decreased the levels of YAP and receptor kinase AXL, a downstream target of YAP. Together, our data suggest that, due to their chemical structures, porphyrin- and dipyrrin-related derivatives can directly target YAP and/or TAZ proteins and inhibit TEAD transcriptional activity.Entities:
Keywords: Hippo pathway; cancer; dipyrrins; non-photoinduced therapy; verteporfin
Mesh:
Substances:
Year: 2017 PMID: 28334506 DOI: 10.1002/cmdc.201700063
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466